Ingrid Desar1, Carla M.L. van Herpen1, J. J.A. van Asten2, W. Fiedler3, A.S. Govaerts4, J. N.H. Timmer-Bonte1, E. G.W. ter Voert2, Antonio Lambiase5, C. Bordignon5, A. Heerschap2, H. W.M. van Laarhoven1
1Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 2Radiology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 3Universitts-Krankenhaus Hamburg-Eppendorf, Hamburg, Germany; 4EORTC Headquarters, Brussels, Belgium; 5Molmed, Milan, Italy
Vascular targeted TNF, NGR-hTNF, has antivascular properties. In a recent phase I study, it was not possible to select an optimal biological dose of NGR-hTNF from DCE-MRI measurements.(1) This study aims to examine the reasons for this. Our results suggests that this was caused by a combination of the following factors: (i) less adequate reproducibility in healthy liver tissue due to more than expected heterogeneity in vascular response, (ii) more than expected changes in healthy liver tissue which influences the amount of contrast between metastases and healthyliver tissue (iii) difference in the effect of NGR-hTNF between tumors related to tumor size and (iv) the development of soluble TNF receptors.